Burdt MA, Hoffman, Robert W., Deutscher, Susan L., Wang, Grace S., Johnson, Jane C., Sharp, Gordon C. (1 May 1999). "Long-term outcome in mixed connective tissue disease: Longitudinal clinical and serologic findings". Arthritis & Rheumatism. 42 (5): 899–909. doi:10.1002/1529-0131(199905)42:5<899::AID-ANR8>3.0.CO;2-L. PMID10323445.
Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA (January 2000). "Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists". Archives of Pathology & Laboratory Medicine. 124 (1): 71–81. doi:10.5858/2000-124-0071-GFCUOT. PMID10629135.
Tan EM, Feltkamp, TE, Smolen, JS, Butcher, B, Dawkins, R, Fritzler, MJ, Gordon, T, Hardin, JA, Kalden, JR, Lahita, RG, Maini, RN, McDougal, JS, Rothfield, NF, Smeenk, RJ, Takasaki, Y, Wiik, A, Wilson, MR, Koziol, JA (September 1997). "Range of antinuclear antibodies in "healthy" individuals". Arthritis and Rheumatism. 40 (9): 1601–11. doi:10.1002/art.1780400909. PMID9324014.
Richardson B, Epstein, WV (September 1981). "Utility of the fluorescent antinuclear antibody test in a single patient". Annals of Internal Medicine. 95 (3): 333–8. doi:10.7326/0003-4819-95-3-333. PMID7023311.
Wenzel J, Gerdsen, R, Uerlich, M, Bauer, R, Bieber, T, Boehm, I (December 2001). "Antibodies targeting extractable nuclear antigens: historical development and current knowledge". The British Journal of Dermatology. 145 (6): 859–67. doi:10.1046/j.1365-2133.2001.04577.x. PMID11899137. S2CID45350044.
Hernández-Molina G, Leal-Alegre, G, Michel-Peregrina, M (January 2011). "The meaning of anti-Ro and anti-La antibodies in primary Sjögren's syndrome". Autoimmunity Reviews. 10 (3): 123–5. doi:10.1016/j.autrev.2010.09.001. PMID20833272.
Kassan SS, Moutsopoulos, HM (June 2004). "Clinical manifestations and early diagnosis of Sjögren syndrome". Arch Intern Med. 164 (12): 1275–84. doi:10.1001/archinte.164.12.1275. PMID15226160.
Ben-Chetrit E (May 1993). "The molecular basis of the SSA/Ro antigens and the clinical significance of their autoantibodies". British Journal of Rheumatology. 32 (5): 396–402. doi:10.1093/rheumatology/32.5.396. PMID8495261.
von Mühlen CA, Tan, EM (April 1995). "Autoantibodies in the diagnosis of systemic rheumatic diseases". Seminars in Arthritis and Rheumatism. 24 (5): 323–58. doi:10.1016/S0049-0172(95)80004-2. PMID7604300.
Benito-Garcia E, Schur, PH, Lahita, R, American College of Rheumatology Ad Hoc Committee on Immunologic Testing, Guidelines (Dec 15, 2004). "Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests". Arthritis and Rheumatism. 51 (6): 1030–44. doi:10.1002/art.20836. PMID15593352.
Jimenez SA, Derk, CT (Jan 6, 2004). "Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis". Annals of Internal Medicine. 140 (1): 37–50. doi:10.7326/0003-4819-140-2-200401200-00013. PMID14706971.
Mahler M, Silverman ED, Schulte-Pelkum J, Fritzler MJ (September 2010). "Anti-Scl-70 (topo-I) antibodies in SLE: Myth or reality?". Autoimmun Rev. 9 (11): 756–60. doi:10.1016/j.autrev.2010.06.005. PMID20601198.
Guldner HH, Szostecki, C, Vosberg, HP, Lakomek, HJ, Penner, E, Bautz, FA (1986). "Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I". Chromosoma. 94 (2): 132–8. doi:10.1007/BF00286991. PMID2428564. S2CID24851422.
Schmidt WA, Wetzel, W, Friedländer, R, Lange, R, Sörensen, HF, Lichey, HJ, Genth, E, Mierau, R, Gromnica-Ihle, E (2000). "Clinical and serological aspects of patients with anti-Jo-1 antibodies—an evolving spectrum of disease manifestations". Clinical Rheumatology. 19 (5): 371–7. doi:10.1007/s100670070030. PMID11055826. S2CID3014699.
Weinstein A, Bordwell, B, Stone, B, Tibbetts, C, Rothfield, NF (February 1983). "Antibodies to native DNA and serum complement (C3) levels. Application to diagnosis and classification of systemic lupus erythematosus". The American Journal of Medicine. 74 (2): 206–16. doi:10.1016/0002-9343(83)90613-7. PMID6600582.
Worman HJ, Courvalin, JC (June 2003). "Antinuclear antibodies specific for primary biliary cirrhosis". Autoimmunity Reviews. 2 (4): 211–7. doi:10.1016/S1568-9972(03)00013-2. PMID12848948.
Mahler M, Raijmakers, R (August 2007). "Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights". Autoimmunity Reviews. 6 (7): 432–7. doi:10.1016/j.autrev.2007.01.013. PMID17643929.
Mahler M, Meroni PL, Andrade LE, Khamashta M, Bizzaro N, Casiano CA, Fritzler MJ (2016). "Towards a better understanding of the clinical association of anti-DFS70 autoantibodies". Autoimmunity Reviews. 15 (2): 198–201. doi:10.1016/j.autrev.2015.11.006. PMID26588998.
Granito A, Muratori P, Quarneti C, Pappas G, Cicola R, Muratori L (January 2012). "Antinuclear antibodies as ancillary markers in primary biliary cirrhosis". Expert Review of Molecular Diagnostics. 12 (1): 65–74. doi:10.1586/erm.11.82. PMID22133120. S2CID28444340.
González-Buitrago JM, González, C (March 2006). "Present and future of the autoimmunity laboratory". Clinica Chimica Acta; International Journal of Clinical Chemistry. 365 (1–2): 50–7. doi:10.1016/j.cca.2005.07.023. PMID16126186.
Emlen W, O'Neill, L (September 1997). "Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays". Arthritis and Rheumatism. 40 (9): 1612–8. doi:10.1002/art.1780400910. PMID9324015.
Frokjaer VG, Mortensen, Erik L., Nielsen, Finn Å., Haugbol, Steven, Pinborg, Lars H., Adams, Karen H., Svarer, Claus, Hasselbalch, Steen G., Holm, Soeren, Paulson, Olaf B., Knudsen, Gitte M. (29 February 2008). "Frontolimbic Serotonin 2A Receptor Binding in Healthy Subjects Is Associated with Personality Risk Factors for Affective Disorder". Biological Psychiatry. 63 (6): 569–576. doi:10.1016/j.biopsych.2007.07.009. PMID17884017. S2CID25979780.
Charles PJ, Smeenk, R. J. T., De Jong, J., Feldmann, M., Maini, R. N. (1 November 2000). "Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trials". Arthritis & Rheumatism. 43 (11): 2383–2390. doi:10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D. PMID11083258.
Burdt MA, Hoffman, Robert W., Deutscher, Susan L., Wang, Grace S., Johnson, Jane C., Sharp, Gordon C. (1 May 1999). "Long-term outcome in mixed connective tissue disease: Longitudinal clinical and serologic findings". Arthritis & Rheumatism. 42 (5): 899–909. doi:10.1002/1529-0131(199905)42:5<899::AID-ANR8>3.0.CO;2-L. PMID10323445.
Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA (January 2000). "Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists". Archives of Pathology & Laboratory Medicine. 124 (1): 71–81. doi:10.5858/2000-124-0071-GFCUOT. PMID10629135.
Tan EM, Feltkamp, TE, Smolen, JS, Butcher, B, Dawkins, R, Fritzler, MJ, Gordon, T, Hardin, JA, Kalden, JR, Lahita, RG, Maini, RN, McDougal, JS, Rothfield, NF, Smeenk, RJ, Takasaki, Y, Wiik, A, Wilson, MR, Koziol, JA (September 1997). "Range of antinuclear antibodies in "healthy" individuals". Arthritis and Rheumatism. 40 (9): 1601–11. doi:10.1002/art.1780400909. PMID9324014.
Richardson B, Epstein, WV (September 1981). "Utility of the fluorescent antinuclear antibody test in a single patient". Annals of Internal Medicine. 95 (3): 333–8. doi:10.7326/0003-4819-95-3-333. PMID7023311.
Wenzel J, Gerdsen, R, Uerlich, M, Bauer, R, Bieber, T, Boehm, I (December 2001). "Antibodies targeting extractable nuclear antigens: historical development and current knowledge". The British Journal of Dermatology. 145 (6): 859–67. doi:10.1046/j.1365-2133.2001.04577.x. PMID11899137. S2CID45350044.
Hernández-Molina G, Leal-Alegre, G, Michel-Peregrina, M (January 2011). "The meaning of anti-Ro and anti-La antibodies in primary Sjögren's syndrome". Autoimmunity Reviews. 10 (3): 123–5. doi:10.1016/j.autrev.2010.09.001. PMID20833272.
Kassan SS, Moutsopoulos, HM (June 2004). "Clinical manifestations and early diagnosis of Sjögren syndrome". Arch Intern Med. 164 (12): 1275–84. doi:10.1001/archinte.164.12.1275. PMID15226160.
Ben-Chetrit E (May 1993). "The molecular basis of the SSA/Ro antigens and the clinical significance of their autoantibodies". British Journal of Rheumatology. 32 (5): 396–402. doi:10.1093/rheumatology/32.5.396. PMID8495261.
von Mühlen CA, Tan, EM (April 1995). "Autoantibodies in the diagnosis of systemic rheumatic diseases". Seminars in Arthritis and Rheumatism. 24 (5): 323–58. doi:10.1016/S0049-0172(95)80004-2. PMID7604300.
Benito-Garcia E, Schur, PH, Lahita, R, American College of Rheumatology Ad Hoc Committee on Immunologic Testing, Guidelines (Dec 15, 2004). "Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests". Arthritis and Rheumatism. 51 (6): 1030–44. doi:10.1002/art.20836. PMID15593352.
Jimenez SA, Derk, CT (Jan 6, 2004). "Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis". Annals of Internal Medicine. 140 (1): 37–50. doi:10.7326/0003-4819-140-2-200401200-00013. PMID14706971.
Mahler M, Silverman ED, Schulte-Pelkum J, Fritzler MJ (September 2010). "Anti-Scl-70 (topo-I) antibodies in SLE: Myth or reality?". Autoimmun Rev. 9 (11): 756–60. doi:10.1016/j.autrev.2010.06.005. PMID20601198.
Guldner HH, Szostecki, C, Vosberg, HP, Lakomek, HJ, Penner, E, Bautz, FA (1986). "Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I". Chromosoma. 94 (2): 132–8. doi:10.1007/BF00286991. PMID2428564. S2CID24851422.
Schmidt WA, Wetzel, W, Friedländer, R, Lange, R, Sörensen, HF, Lichey, HJ, Genth, E, Mierau, R, Gromnica-Ihle, E (2000). "Clinical and serological aspects of patients with anti-Jo-1 antibodies—an evolving spectrum of disease manifestations". Clinical Rheumatology. 19 (5): 371–7. doi:10.1007/s100670070030. PMID11055826. S2CID3014699.
Weinstein A, Bordwell, B, Stone, B, Tibbetts, C, Rothfield, NF (February 1983). "Antibodies to native DNA and serum complement (C3) levels. Application to diagnosis and classification of systemic lupus erythematosus". The American Journal of Medicine. 74 (2): 206–16. doi:10.1016/0002-9343(83)90613-7. PMID6600582.
Worman HJ, Courvalin, JC (June 2003). "Antinuclear antibodies specific for primary biliary cirrhosis". Autoimmunity Reviews. 2 (4): 211–7. doi:10.1016/S1568-9972(03)00013-2. PMID12848948.
Mahler M, Raijmakers, R (August 2007). "Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights". Autoimmunity Reviews. 6 (7): 432–7. doi:10.1016/j.autrev.2007.01.013. PMID17643929.
Mahler M, Meroni PL, Andrade LE, Khamashta M, Bizzaro N, Casiano CA, Fritzler MJ (2016). "Towards a better understanding of the clinical association of anti-DFS70 autoantibodies". Autoimmunity Reviews. 15 (2): 198–201. doi:10.1016/j.autrev.2015.11.006. PMID26588998.
Granito A, Muratori P, Quarneti C, Pappas G, Cicola R, Muratori L (January 2012). "Antinuclear antibodies as ancillary markers in primary biliary cirrhosis". Expert Review of Molecular Diagnostics. 12 (1): 65–74. doi:10.1586/erm.11.82. PMID22133120. S2CID28444340.
González-Buitrago JM, González, C (March 2006). "Present and future of the autoimmunity laboratory". Clinica Chimica Acta; International Journal of Clinical Chemistry. 365 (1–2): 50–7. doi:10.1016/j.cca.2005.07.023. PMID16126186.
Emlen W, O'Neill, L (September 1997). "Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays". Arthritis and Rheumatism. 40 (9): 1612–8. doi:10.1002/art.1780400910. PMID9324015.
Frokjaer VG, Mortensen, Erik L., Nielsen, Finn Å., Haugbol, Steven, Pinborg, Lars H., Adams, Karen H., Svarer, Claus, Hasselbalch, Steen G., Holm, Soeren, Paulson, Olaf B., Knudsen, Gitte M. (29 February 2008). "Frontolimbic Serotonin 2A Receptor Binding in Healthy Subjects Is Associated with Personality Risk Factors for Affective Disorder". Biological Psychiatry. 63 (6): 569–576. doi:10.1016/j.biopsych.2007.07.009. PMID17884017. S2CID25979780.
Petri M, Karlson, EW, Cooper, DS, Ladenson, PW (October 1991). "Autoantibody tests in autoimmune thyroid disease: a case-control study". The Journal of Rheumatology. 18 (10): 1529–31. PMID1765977.
Charles PJ, Smeenk, R. J. T., De Jong, J., Feldmann, M., Maini, R. N. (1 November 2000). "Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trials". Arthritis & Rheumatism. 43 (11): 2383–2390. doi:10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D. PMID11083258.
Medina-Rodriguez F, Guzman, C, Jara, LJ, Hermida, C, Alboukrek, D, Cervera, H, Miranda, JM, Fraga, A (November 1993). "Rheumatic manifestations in human immunodeficiency virus positive and negative individuals: a study of 2 populations with similar risk factors". The Journal of Rheumatology. 20 (11): 1880–4. PMID8308773.
Cervera R, Font, J, Ramos-Casals, M, García-Carrasco, M, Rosas, J, Morlà, RM, Muñoz, FJ, Artigues, A, Pallarés, L, Ingelmo, M (2000). "Primary Sjögren's syndrome in men: clinical and immunological characteristics". Lupus. 9 (1): 61–4. doi:10.1177/096120330000900111. PMID10713648. S2CID39696993.
Wenzel J, Gerdsen, R, Uerlich, M, Bauer, R, Bieber, T, Boehm, I (December 2001). "Antibodies targeting extractable nuclear antigens: historical development and current knowledge". The British Journal of Dermatology. 145 (6): 859–67. doi:10.1046/j.1365-2133.2001.04577.x. PMID11899137. S2CID45350044.